Ortoma Engages M&A Advisor

Published May 2, 2019

Ortoma and the Board of Directors have engaged MedWorld Advisors (www.medworldadvisors.com) as M&A advisor to assist the company and the Board with management, evaluations, and negotiations in connection with any M&A transaction.

During the past year, the company have had discussions with potential industrial partners as a part of taking its product Ortoma Treatment Solution to the market. MedWorld Advisors will take over the contacts that have been generated by the company, broaden and intensify the evaluation, and negotiate with potential acquirers and industrial partners.

Linus Byström, CEO, comments: “In the past months, we have evaluated various M&A advisors to assist the company with an M&A transaction. MedWorld Advisors specializes in assisting small and medium-sized medtech companies, and has been engaged since they are represented in Europe, the US and Asia, in combination with having years of experience with M&A transactions, both on the buy side and the sell side. ”

Ortoma Treatment Solution™ – careful planning and precise surgery.

This information is information that Ortoma Ab (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 2 of May 2019.

For more information, please contact:
Ortoma CEO Linus Byström, or chairman of the board Gunnar Németh
Email: [email protected]

Ortoma AB utvecklar operationssystem för planering och positionering av implantat vid höftleds-, knäleds- och ryggkirurgi. Syftet med bolagets operationssystem, Ortoma Treatment SolutionTM (OTS) är att göra det möjligt för kirurgen att inför operation med stor precision mäta och planera i 3D för placeringen av ett ledimplantat och under operation på ett optimalt sätt positionera implantatet i patienten. Ortomas operationssystem syftar till att ge ett bättre operationsutfall för patienten, med färre komplikationer och färre efterföljande operationer – och därmed bättre långtidsöverlevnad av implantat. Ett andra syfte är att skapa ett system som enkelt kan integreras i de processer och rutiner som idag används vid operationer – och därmed öka effektiviteten. Ortoma har cirka 1 600 aktieägare och bolagets B-aktie är noterad på Spotlight Stock Market. Globalt genomförs mer än 7,5 miljoner ortopediska ingrepp varje år där OTS kan komma användas inom höftleds-, knäleds- och ryggkirurgi. I Sverige genomfördes föregående år cirka 42 000 ingrepp inom höftleds-, knäleds- och ryggkirurgi.

Press release in PDF

About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Nasdaq First North Growth Market Stockholm.